• Nuclear Medicine and Molecular Imaging
• /
• 제40권1호
• /
• pp.48-50
• /
• 2006

A 38-year-old female with arthralgia in right elbow joint for 6 months was referred for a bone scan which showed diffuse uptakes of $^{99m}Tc$-MDP in the liver and spleen without hepatosplenomegaly. She had a history of hepatitis B vaccination 3 days ago. These uptakes were disappeared on the follow-up bone scan after 4 months. We suggest this transient diffuse hepatic uptake after vaccination of hepatitis B might be due to aluminum component within the hepatitis B vaccine as adjuvant.

• 약학회지
• /
• 제47권2호
• /
• pp.110-119
• /
• 2003

The purpose of the present study was to kinetically investigate the carrier-mediated uptake in the hepatic transport of organic anions, and to simulate the ″in vivo counter-transport″ phenomena, using kinetic model which was developed in this study. The condition that the mobility of carrier-ligand complex is greater than that of free carrier is not essential for the occurrence of ″counter-transport″ phenomenon. To examine the inhibitory effects on the initial uptake of a ligand by the liver, it is necessary to judge whether the true counter-transport mechanism (trans-stimulation) is working or not. The initial plasma disappearance curves of a organic anion were then kinetically analyzed based on a flow model, in which the ligand is eliminated only from the peripheral compartment (liver compartment). Moreover, ″in vive counter-transport″ phenomena were simulated based on the perfusion model which incorporated the carrier-mediated transport and the saturable intracellular binding. The ″in vivo counter-transport″ phenomena in the hepatic transport of a organic anion were well demonstrated by incorporating the carrier-mediated process. However, the ″in vivo counter-transport″ phenomena may be also explained by the enhancement of back diffusion due to the displacement of intracellular binding. In conclusion, one should be more cautious in interpreting data obtained from so-called ″in vivo counter-transport″ experiments.

• 대한핵의학회지
• /
• 제25권2호
• /
• pp.200-206
• /
• 1991

Arterial fraction of total hepatic blood flow was estimated by a new method, slope method, on radionuclid angiogram using $^{99m}Tc-DISIDA$ and was compared with that from $^{99m}Tc-Phytate$ radionuclide angiogram. This study included 11 of normal subjects, 37 of intermediate group with various liver diseases, and 25 patients with liver cirrhosis. We analyzed the datas with slope method from radionuclide angiograms and the results were compared with hepatic arterial fractions from uptake method, introduced by Lee et al. at 1986. The hepatic arterial fractions from radionuclide angiograms using $^{99m}Tc-DISIDA$ and $^{99m}Tc-Phytate$ were $0.32{\pm}0.09\;and\;0.31{\pm}0.11$ respectively in normal subjects, and $0.75{\pm}0.18\;and\;0.77{\pm}0.21$ respectively in patients with liver cirrhosis. The hepatic arterial fractions by the slope method was well correlated with those of the uptake method on $^{99m}Tc-DISIDA$ scan. There was high correlation between the hepatic arterial fractions from $^{99m}Tc-DISIDA$ and $^{99m}Tc-Phytate$ scans. Hepatic arterial fraction estimated by the slope method is a useful index for the diagnosis of liver cirrhosis and the evaluation of status of portal hypertension.

• 대한핵의학회지
• /
• 제4권2호
• /
• pp.41-53
• /
• 1970

Although the radioisotope liver scan has primarily been of use in the detection of the intra-hepatic space occupying lesions, there has been an increasing awareness of its use in evaluation of liver function. In this study, the degree of hepatomegaly, changes in shape and mottling radiodensity on each lobe and splenic visualization in the liver scans done with colloidal radiogold were numerically expressed as scores under the arbitrary standard in 210 patients with liver cirrhosis. The clinical value of this scoring system was studied with special regards to the correlation between the radiogold hepatic uptake half time and conventional liver function tests. Following were the results; 1) The normal scan appeared in 6.7% of 210 patients with liver cirrhosis. 2) The colloidal radiogold hepatic uptake half time was abnormally and progressively prolonged in parallel to severity of hepatocellular dysfunction. The mean hepatic uptake half time in cirrhosis showing normal scan was $2.76{\pm}0.73$ minutes. 3) The scoring system was well correlated with the serum albumin and globulin levels, A/G ratio and BSP retention. There was some correlative tendency in alkaline phosphatase activity. 4) There was no correlation with the thymol turbidity test, cholesterol levels, transaminase activities and bilirubin levels. 5) The spleen was visualized in 38.6% of total patients with liver cirrhosis. Excluding normal scans in liver cirrhosis, the spleen was visualized in 41.3%. 6) The scoring system appears to confirm the clinical diagnosis and to give a reliable estimate of the degree of hepatocellular dysfunction in patients with liver cirrhosis.

• 핵의학기술
• /
• 제16권2호
• /
• pp.57-61
• /
• 2012

전신 뼈 검사에 이용되는 방사성의약품의 주된 집적부위는 뼈 무기질이며 그 섭취기전은 명백히 밝혀져 있지 않다. 전신 뼈 검사에서 일시적으로 미만성 간 섭취가 나타날 수 있으며, 간내 섭취의 원인은 다양하게 보고되고 있다. 본 연구에서는 전신 뼈 검사에서 $^{99m}Tc$-DPD의 미만성 간 섭취에 MRI 조영제가 미치는 영향을 알아보았다. 2010년 1월부터 12월 사이에 $^{99m}Tc$-DPD 전신 뼈 검사를 시행한 환자 중 982명을 연구의 대상으로 하였다. 982명의 환자는 전신 뼈 검사 이전에 MRI 조영제를 사용한 검사를 시행하였다. 혈액학검사 및 일반화학검사 소견을 조사한 결과 전신 뼈 검사에서 46명의 환자(남:여=39:7)가 미만성 간 섭취를 보였다. 추적 전신 뼈 검사를 시행하였으며, 이전에 보였던 미만성 간 섭취는 모두 소실되어 정상적인 소견을 보였다. 간기능 및 신기능 검사는 모두 정상이었다. 전신 뼈 검사에서 $^{99m}Tc$-DPD의 미만성 간 섭취에 MRI 조영제가 간접적인 영향을 주고 있다. $^{99m}Tc$-DPD의 미만성 간 섭취를 피하기 위해서 전신 뼈 검사는 MRI 조영제를 사용한 검사를 시행하기에 앞서서 먼저 시행하여야 하고, MRI 조영제를 사용한 검사가 있을 경우에는 조영제가 몸에서 제거된 후 검사를 시행하여야 할 것이다.

• 한국임상약학회지
• /
• 제3권2호
• /
• pp.163-168
• /
• 1993

The influence of cimetidine pretreatment(100mg/kg, single i.p.) on the hepatic blood flow was investigated using pharmacokinetic parameters of indocyanine green(ICG) in the rat on the basis of hepacc perfusion-limited model. ICG(1mg/kg) was respectively administered via femoral and portal vein to the control and to the cimetidine-pretreated rats. The rate constant K12, K20 and the systemic clearance(CLt) of ICG were significantly(p<0.05) decreased ill the cimetidine-pretrea-to(B rats, but no significant diffirences were observed in hematocrit and liver weight. The biliary excretion rates of ICG were also decreased regardless of the route of administration in the cimetidine-pretreated rats. And also the hepatic blood flow in rats was decreased about $16\%$ by cimetidine. It may be concluded that the decreased hepatic blood flow with cimetidine mainly contributed to the decreased hepatic uptake and the decreased systemic clearance of ICG.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.422.2-423
• /
• 2002

The purpose of the present study was to investigate the hepatic uptake and biliary excretion of IH-901. a potential anticancer agents. in rats. IH-901 was mainly distributed into the liver after its iv administration at the dose of 10-30 mg/kg. The liver concentration of IH-901 at 7 min after its Iv administration was comparable with its initial concentration of the plasma. Moreover. recovery ratio of IH-901 in the bile for 6 hr was more than 40% after its iv administration. (omitted)

• 대한핵의학회지
• /
• 제33권1호
• /
• pp.49-56
• /
• 1999

목적: T1-201 경직장 문맥신티그라피에서 심장/간 섭취비(단락지수)는 만성 간질환 환자에서 문맥-체단락을 평가하는 데 유용한 지표로 알려져 있다. 본 연구는 만성 활동성 간염과 간경변 환자에서 T1-201 섭취 양상과 초기 간/심장 섭취속도의 유용성을 평가하고, 단락지수와의 연관성을 알아보고자 하였다. 대상 및 방법: 간생검으로 만성 간질환(만성 활동성 간염 35명, 간경화 23명)을 진단받은 58명의 환자에서 T1-201 18.5 MBq를 상부직장에 주입 후 T1-201 경직장 문맥신티그라피를 시행하였다. 간섭취 양상(1형: 균일 분포, 2형: 분절단위 불균일 분포, 3형: 비분절단위 불균일 분포)과 비장, 심장, 신장의 간외 분포양상(grade 0: 방사능 섭취 없음, grade 1: 간보다 적은 방사능 정도, grade 2: 간과 비슷한 방사능 정도, grade 3: 간보다 많은 방사능 정도), 초기 간/심장 섭취속도(처음 10분간의 간/심장 섭취비의 기울기)와 단락지수(심장/간 계수비)를 구하였다. T1-201 섭취 양상과 초기 간/심장 섭취비를 병리진단, 단락지수와 비교하였다. 결과: 간 섭취 양상은 만성 활동성 간염에서 1형과 2형의 간내 방사능 분포 양상이 많았고(만성 활동성 간염: 27/35, 간경변: 8/23), 간경변은 3형이 유의하게 많았다(만성활동성 간염. 8/35, 간경변: 15/23)(p<0.005). 간외분포양상의 grade는 간경변에서 유의하게 높았다(비장: p<0.001, 기타 연 조직 p<0.005). 초기 간/심장섭취속도는 만성 활동성 간염($0.110{\pm}$0.111)이 간경변($0.014{\pm}0.090$)보다 유의하게 높았으며(p<0.001), 간경변의 판정지표로서 0.05를 기준으로 하였을 때 예민도와 특이도는 각각 77.2%, 67.7%였다. 초기간/심장 섭취속도와 단락지수는 음의 상관관계를 보였다(r=-0.3347, p<0.01). 결론: T1-201 경직장 문맥 신티그라피에서 간 및 간외 방사능 분포와 초기 간/심장 섭취속도는 만성 간질환 환자에서 문맥-체단락을 평가하는 데 유용한 지표로 생각된다.

• 대한핵의학회지
• /
• 제32권1호
• /
• pp.114-119
• /
• 1998

반복적인 수혈을 받은 급성전격성간염 환자에서 Ga-67 체내분포의 양상을 추적하였다. 급성기에 시행한 갈륨스캔에서 간의 악성종양을 의심하게 하는 간섭취증가와 신장, 뼈섭취증가가 관찰되었다. 간섭취증가는 철운반단백질에 결합하지 않은 Ga-67이 염증이 일어난 간세포에 섭취되었기 때문으로 해석되었다. 신장과 뼈섭취증가는 반복적인 수혈에 의한 철운반단백질의 포화에 따른 Ga-67의 세포내운반저하에 의한 것으로 생각되었다. 10개월 후에 다시 시행한 갈륨스캔에서 간섭취는 더욱 증가되었으며 골수섭취의 증가가 관찰되었다. 반면 신장섭취는 정상화되었다. 이러한 소견은 철결핍성 빈혈에 의한 것으로 해석되었다. 이 증례는 체내 철의 양과 이에 따른 철운반단백질 포화도의 변화에 의한 Ga-67의 체내분포의 변화를 예시해 준다.

• Journal of Pharmaceutical Investigation
• /
• 제22권4호
• /
• pp.289-300
• /
• 1992

The counter-transport phenomena in the hepatic transport of 1-anilino-8-naphthalene sulfonate (ANS) were kinetically investigated by analyzing the plasma disappearance-time profiles and the transport into the isolated hepatocytes. In vivo "counter transport phenomena" were simulated based on the perfusion model which incorporated the carrier-mediated transport and the saturable intracellular binding. The condition that the mobility of carrier-ligand complex is greater than that of free carrier is not essential for the occurrence of counter-transport phenomenon. To examine the inhibitory effects on the initial uptake of a ligand by the liver, it is necessary to judge whether the true counter-transport mechanism (trans-stimulation) is working or not. The initial plasma disappearance curves of ANS were then kinetically analyzed based on a two-compartment model, in which the ligand is eliminated only from the peripheral compartment (liver compartment). No effects on the initial plasma disappearance rates of ANS were observed after preloading of bromophenol blue (BPB) or rose bengal (RB) in the liver. Inhibitory effect of BPB or RB on the initial uptake (or efflux) rates of ANS by the isolated hepatocytes were not observed, suggesting that the true counter transport mechanism is not working. In conclusion, checking the preloading effects of transstimulation on the initial uptake of a ligand by the liver could be a useful criterion for carrier cycling and common use of the same carrier between two ligands. However, one cannot exclude those possibilities even if the preloading effects cannot be observed.